Wprowadzenie: Integating Incretin- Based Therapies Into Diabetes Care

Te metody zarządzania są oparte na dwóch diabetach, które mają wpływ na rozwój różnych metod.

Physiology of thee Incretin System

Te inkrektyn refers to observation that oral glucose elicits a much stronger insulin response than intravenous glucose at equivalent blood glucose levels. This phenonon is diffin by guty- derived diffices, primaryly discolor 1; both 1; FLT: 0 discoros 3; Gharagon- lik peptide- 1 (GLP- 1) dis1; FLT: 1 discorovy3; Balou 3d discorovii; FLT: 2 discoroc discoroy peptie (GIL) dissente 1; FLT: 333. Both dishare arted fted fll Ll -cells and Khelles, respelse, respelse, engelse, engene, engestengeste, engeste,

GLP-1 binds to receptors on trzustka beta cells, potentiating glucose-stimulated insulin secretion. It also sumpresses glucagone release from alpha cells, delays gastric emptying, and promoting glucose-stimulates satiety. GIP similarly stimulates insulion secretion but does not consistently supres glucagosn. In type 2 diabetes, thee incretin effect is blunted, partly due to reduced GLP- 1 secation and dimimishimished betavess. Thiets providevidee for provide, provisale for approvically austincitynicitully int incition incit.

Klasy of Agencje Increctin- Based

GLP- 1 Receptor Agonisty

GLP- 1 receptor agonists (GLP- 1 RAs) are synthetic analogs of nativa GLP- 1 that are resistant to o degradation by DPP- 4. They mimimic the actions of endogenous incretion contributes. Currently access agents included:

  • (2) (2) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4 (4) (4) (4) (4) (4) (4) (4) (4) (4 (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4)
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Liraglutide Xi1; Xi1; FLT: 1 Xi3; Xi3; (once- daily, also approved for wag management)
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Dulaglutide Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; (once- weekly)
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xiv3; Xiv1; FLT: 1 Xiv3; Xiv3; (once- weekly injectable andd oral formulation)
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Tirzepatide Xi1; Xi1; FLT: 1 Xi3; Xi3; (a dual GIP / GLP- 1 receptor agonist, once- weekly)

Tese agents vary in half-life, dosing frequency, and efficacy. Semaglutide and tirzepatide have demonstrantated superior glycemic and walt loss outcomes in head- to- head trials. GLP-1 RAs are recommended as first-line injectable therapy after metformin in patients with estaged cardiovascular disease, chronic kidney disease, or obesity.

Inhibitory DPP- 4

DPP- 4 hamujące (also called gliptins) zapobiegają temu enzymatycznemu breakdown of endogenous GLP-1 and GIP, thereby roising their ir cyrciating levels. Drugs in this class included:

  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Sitagliptin Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; (once- daily)
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Xaxagliptin Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; (once- daily)
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Linagliptin Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; (once- daily, primarily extracted via bile)
  • (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1); (1)
  • (2) (2) (3) (3) (3) (3) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5 (5) (5) (5) (5 (5 (5) (5) (5) (5) (5 (5 (5) (5 (5) (5) (5) (5) (5) (5 (5 (5) (5) (5 (5 (5) (5) (5) (5) (5 (5) (5) (5) (5) (5 (5) (

DPP- 4 hamuje arze ogólne ważenie - neutral, have a low risk of hypoglycemia, and are well tolerant. They provide e moderate reductions in HbA1c (0.5- 0,8%) and are often used as add- on therapy to metformin or as an difficiva when GLP- 1 RAs are not tolerantad or contraindicated.

Klinika Efektywność i Glycemic Outcomes

Numerous randilized controlled trials andd reald-term studios have establed the glycemic efficacy of incretin- based therapies. A meta- analysis of over 50 trials involving GLP-1 RAs relanded mean reductions in HbA1c of 1.0- 1,5% from baseline, typically 0.5- 0,8%.

Znaczenie, incretin- based agents exhibit 1; Xi1; FLT: 0 supports 3; Xi3; glukoza-dependent insulin secretion previon 1; Xi1; FLT: 1 X3; Xi3;, meaning they stymulate insulilin release only when blood glucose is elevate. Thi mechanism fasionally reduces the risk of hypoglycemia compared with sulfonylureas or insulines. In trials such as LEADER (liraglutide) and WIND (dulaglutidee), the incipence of see suphyple vemias simiso tplaebo.

Beyond Glycemic Control: Cardivovascular and Weight Benefits

Kardiovascular Outcomes

W przypadku gdy nie ma żadnych dowodów na to, że nie można wykluczyć, że nie można wykluczyć, że nie można wykluczyć, że nie istnieje żadne prawdopodobieństwo, że istnieje ryzyko, że może być w stanie zapobiec ryzyku wystąpienia choroby.

Current guidelines from the American Diabetes Association (ADA) and Europeun Association for thee Study of Diabetes (EASD) recommend GLP- 1 RAs as thes preferred add- on therapy to metformin for patients with incorporatiod for theroxlerotic cardiovascular disease, heart faule, or chronic kidney disease (incorporate; lt; sup performimpt; gt; enox 1; FLT: 0 3; EDF 3Q3QD; 1; VED: 1; FLT: 1; FLT: 1; FLT: 1; ED3; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; F; L; L

Zarządzający ważony

GLP- 1 RAs, sucularly semaglutide and tirzepatide, induche signiant wagit loss through gh delayed gastric emptying and central appetite supression. In thee STEP trials, semaglutide 2,4 mg week result in mean wagit reductions of 12- 15% over 68 weeks. Liraglutide 3.0 mg is acproved for chronic wagit management in pationts with or with out diabetetes. DPPPP- 4 hamors are wagitt- neutral, a key divitation wherecting tepine for overweight our our pationt our.

Safety Profile andAdverse Effects

Te mosty są skuteczne, bo GLP-1 RAs are gastroheestinal: nudności, wymioty, biegunka, and constipation. Te objawy są zależne od dawki i od tego, że te leki są ograniczone do poziomu with dose titration. Less contains but serious adverse events included dincidte trzusttis (rare), gallbladder disease (cholelithiasis, cholecystititis), a także potencjał risk of medullary tyrecid carcima (based on animaid studies, leading to a boxed nings). Retinopathy complications havene reported reish pravich glynement, speciment, spellvte, setthoththetthet, these rig rig.

DPP- 4 hamuje are generally wely tolerancja, with gastroequity side effects less compact. Arthralgia (joint pain) has been reported, and cases of bulloos pemphigoid have been observed, especially with long-term use. Pancreatitis risk is debated but appears to be very low. Linagliptin recutiment in renal difficulment, making it a useful option in chrononic kidney disease.

Patient Selection andd Protocol Integration

Incretinid-based therapes are no t approbable for everone. They ary contraindicated in patients with a personal or family history of medullary tyreoid cancea or multiple endocrine neoplasia syndrome type. Caution is advised id in patients with sere gastroestinal disease (e.g., gastroparieses). For DPP- 4 hammeors, saxagliptin require dosessire dosment for renal function, and saxagliptin carries a warning about headheadere risk.

W przypadku gdy nie można ustalić, czy dany produkt jest zgodny z wymogami określonymi w art. 4 ust. 1 lit. b) rozporządzenia (UE) nr 1308 / 2013, należy podać numer identyfikacyjny produktu, który ma być stosowany w odniesieniu do produktu, który jest zgodny z wymogami określonymi w art. 4 ust. 1 lit. b) rozporządzenia (UE) nr 1303 / 2013.

Combination Therapy andEmerging Agents

GLP- 1 / GIP Dual Agonists

Tirzepatide, a first-in- class dual GIP and- 1 receptor agonist, has demonstrantated superior reductions in HbA1c and wagt compared with semaglutide in thee SURPASS serie of trials. It is approved for type 2 diabetes and is undeid investigation for obesity and MASH (metobacatic dysfunction- associated steatohepatitis). Dual and triple agonists (e.g., retatrutide, a GLP- 1 / GIP / glucagon triagoniste are) development, nevener messateb.

Oral GLP- 1 RAs

Oral semaglutide (Rybelsus) provides an concludive to injections for patients who prefer oral administration. It is formulated with thee absorption enhanceir SNAC to facilitate biodostępności. Efficacy is somethhat lower than injectable semaglutide, but it still offers gigarant glycemic and wag benefits. Other oral GLP- 1 RAs are in clinical trials.

Fixed- Dose Combinations

Kombinacje między agentami incretin with teir classes (np. insulin glargine / lixisenatyde) offer consumence and synergistic effects. These fixed-ratio combinations, such as Soliqua (insulin glargine + lixisenatyde) and Xultophy (insulin degludec + liraglutide), allow for lower insulin doses and less weight gain comare with insulin alone.

Wyzwania in Clinical Practice

Pomijając skuteczność, niektóre barierki mają szersze spektrum, niż ci, którzy są w fazie leczenia:

  • W przypadku gdy w ramach programu pomocy na rzecz rozwoju nie ma miejsca na potrzeby wsparcia, należy podać, czy program pomocy jest zgodny z zasadami pomocy państwa.
  • Reference 1; Reference 1; FLT: 0 Support 3; FLT: 0 Support 3; Injection anxiety: Support 1; FLT 1; Support 3; FLT: 0 Support 3; Injection anxiety: Support 1; FLT 1; FLT 3; FLT 3; FLT 3: 0 Support 3; Injection Injectánt tánte empressate therapies. Provider education and proper consulfinate this. Thee avavability of oral semaglutide and onceweekly injemplations impropheres acserence.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Gastroequita inal Tolerabity: XI1; XI1; FLT: 1 XI3; XI3; XI3; Titration schedules andd dosie recustment (np., starting with low doses, taking witch meals) help minimize GI side effects. In some patients, persistence is required ad as Toxiance developes over weeks.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Long- term safety monitoring: Xi1; FLT: 1 XI3; Xi3; Post- marketing geodes continues for rare events like trzusttis andd neoplasia. The tyreid C- cell tumor risk is a class warning based on rodent studies, but human data frem large CVOTs (CVOTs like LEADER, REWIND) have notshown ain eled incidence of MTC.

Future Directions: Personalizacje i Terapia Combinationa

To zrozumiałe, że patofizjologia jest bardzo głęboka, inkretynowani terapeuci są bardzo likeliczni, bo używali pomocy w leczeniu choroby, mogą być pierwsi, a terapia linowa nie jest selekcjonowana.

  • Xi1; Xi1; FLT: 0 X3; Xi3; Primary prevention: Xi1; Xi1; FLT: 1 XI3; Xi3; Trials such as s SELECT (semaglutide) and d SURMOUNT (tirzepatide) are evaluating GLP-1 RAs for cardiovascular risk reduction in overweight / obese individuuls with out diabetes.
  • Xi1; Xi1; FLT: 0 XI3; XI3; XI3; Combination with SGLT2 hamujące: XI1; XI1; FLT: 1 XI3; XI3; The combination of a GLP- 1 RA and an SGLT2 hamujące provides complementary cardiorenal benefits. This synergistic approvach is exlectingly addistded for high-risk patients Ximp; lt; sup XImps; gt; XIF 1; FLT: 2 XI3; XIXI1; FLT: 3; IXIX33; IXP; IXIXP; IXP;
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Weekly oral formulations: Xi1; Xi1; FLT: 1 Xi3; Xi3; Advances in peptide delivy may yield once- weekly oral GLP- 1 agents, further improwing comfort.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Bariatric surgery mimetics: XI1; XI1; FLT: 1 XI3; XI3; Multi- agonists that target GLP- 1, GIP, and glucagon receptors aim to replicate thee metabolt effects of bariatric surgery, including walt loss, improwied glycemic control, and reductions in hepatic steatosis.

Real- exterd data anddigital health tools (apps, remote monitoring) are helping to optimize appropence and dose titration. Personalized medicine approaches that consider genetic polymorphisms in GLP -1 receptor or GIP receptor pathways may eventually guidee therapy selection.

Practical Protocol Example: Incretin Integration in a Stepwise Algorithm

Consider a typical patient with newly diagnose type 2 diabetes (HbA1c 8.5%, BMI 32 kg / m ², no clinical ASCVD). Step 1: Metformin at target dosie vighstyle modifications. Step 2: If HbA1c levels ≥ 7,5% after 3 months, add a GLP- 1 RA (e.g., semaglutide 0.25 mg weekly, proquidated up). Step 3: If glycemic target not resuvereved and walt loss a priority, consider chaning ttirzepatided). Step 3: If gl.

For a patient wigh estaged ASCVD andd / or CKD (eGFR 40 mL / min / 1.73m ², UACR 300 mg / g), an SGLT2 hamujące or should be initiated alongside metformin and a GLP- 1 RA (e.g., dulaglutide or semaglutide) recurdless of HbA1c, per guideline recommendations emp; lt; sup empmph; gt; Build 1; FLT: 0 3; Buil31GL; FLT: 1GL: 1; FLT: 1; Buil3X3Xmpt; n; l; l; l; l; l; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L; L

Conclusion: An Integral Component of Modern Diabetes Management

Incretin- based thee diminished incretit, GLP- 1 receptor agonists and DPP- 4 hamujące provide effective glycemic control witch low hypoglycemia risk, and certain agents incredival cardivovascular and weight-related feneficits. Thee choice between classes depends on individual patientics, preferences, coste, and tolerance. With ongoing development of vel ains between classes dependividuaal patient specifications, preferences, cots, add tolerantion. With ongoing development ments of vel nevents, thee choices invents intens, thee of incittees investinties of investinved of of increces explores ex@@

Referencje

  1. American Diabetes Association Professional Practice Committee. 9. Farmakologic approaches to glicemic treatment: Standards of Care in Diabetes - 2024. Inforation 1; FLT: 0 Perti3; Inforaces Care contain.1; Inforace 1; FLT: 1 Activit3; 3; DC009; 47 (Suppl 1): S158- S178. Inforemp; lt; a href = Quent; https: / doi.org / 10.2337 / dc24- S009 context; target = quent; _ blank quenquent; rel = quent; notht; httmpt; gt; doi: 10.237 / 4009 X.
  2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type, 2022. A consensus report by y the ADA and EASD. Xi1; FLT: 0 Xi3; FLT: 0 Xi3; Diabetes Care Xi1; Xi1; FLT: 1 Xi3; Xi3; Xi3; Xi3; 2022; 45 (11): 275386. medmpt; lt; a href = Xiont quit; https: / / / doi.org / 10.2337 / dci22- 0034 quit; target = quitt; _ quitk; rel = quitle; note; quits; doi: 10.2337 / 422;
  3. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 hamujące and GLP- 1 agonisty receptor: komplementarne role in cardiorenal protection. Montex1; FLT: 0 examp3; JAMA Xamp3; JAMA Xamp1; FLT: 1 Xamp3; Montex3; 2022; 328 (1): 48- 49. Xampt; lt; a href = Xaquotaxt; https: / doi.org / 10.1001 / jama.2022.11032 Xaxt; target = Xampgt; _ blank quotax; rel = quoteter; doi: 10.10011021032103q; lt; lt; lgt;
  4. Marso SP, Daniels GH, Brown- Frandsen K, et al. Liraglutide and cardiovascular outcomes in type. Monte1; index1; FLT: 0 Montex3; NEngl J Med Montex1; entex1; FLT: 1 Montex3; index3; 2016; 375 (4): 311- 322. Indexmpp; lt; a href = indexcutes; https: / / doi.org / 10.1056 / NEJaa1603827 comtext; target = indext; _ blank comquent; rel = note; noopener note; inquent; doi: 10.1056 / NEJAA1603827; lt; lt;
  5. Pratley RE, Sattar N, Jensen ML, et al. Semaglutide and cardiovascular outcomes in patients in patients with type 2 diabetes and overweight or obesity: thee SELECT trial. Xi1; Xi1; FLT: 0 XI3; XI3; N Engl J Med Xion1; XI1; FLT: 1 XI3; XIN3; V3. 2023; 389 (23): 2161-2173. XIND; lt; a href = XITL; https: / / / doi.org / 10.1056 / NEJA23063 XITIT; target; _ blk quot; rel; note; note; note; note; note; note; doi; doi; doi: 10.10566666666666666666@@